If you all would read the May 30 press release, you would know that it does not matter the patient date for Celexa. In the press release, Forest announced a marketing agreement for the Big Bother of Celexa. It is "the active enantiomer of Celexa, which will enter clinical studies later this year and is patented until the year 2009." If Celexa sells anything like it has in Europe, Forest will transfer the Celexa sales to the new agent before the patient expires. This has been done successfully by all the pharmaceutical companies.
The anti-depressant market in the U.S. is close to 5 billion dollars. Three of the top ten most prescribed drugs in the U.S. are anti-depressants (Prozac #2, Zoloft #5, Paxil #7 I think?). When Forest reaches a 10% market share with Celexa, it will DOUBLE the size of the company's sales.